| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/21/2005 | US20050158737 Tumour associated antigens |
| 07/21/2005 | US20050158726 Compositons and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 07/21/2005 | US20050158724 Methods, of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 07/21/2005 | US20050158714 Polypeptide nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis |
| 07/21/2005 | US20050158608 Method for manufacturing a layer lamination integrated fuel cell and the fuel cell itself |
| 07/21/2005 | US20050158413 Useful in increasing the effects of nucleic acid vaccines and medicaments; in production of phenotypically immature and/or mature dendritic and/or fibrocyte cells |
| 07/21/2005 | US20050158347 Prophylactic and therapeutic immunization against protozoan infection and disease |
| 07/21/2005 | US20050158346 Vaccine against Haemophilus influenzae type a, Haemophilus influenzae type b, Staphylococcus aureus, and Staphylococcus epidermidis; glycoconjugate of cell wall polysaccharide from Bacillus pumilus Sh 18 |
| 07/21/2005 | US20050158345 ABC (ATP-binding cassette) transporters; polynucleotides, expression vectors, transformed host cells and antibodies; use in vaccination |
| 07/21/2005 | US20050158344 Exoenzyme toxin of aeromonas salmonicida, and uses thereof |
| 07/21/2005 | US20050158343 Non-B, non-C, non-G hepatitis virus gene, polynucleotide, polypeptide, virus particle, method for isolating virus particle, and method for detecting virus |
| 07/21/2005 | US20050158342 Multi plasmid system for the production of influenza virus |
| 07/21/2005 | US20050158341 Tat and Nef to promote localized accumulation of CD4+ cells, and a compound that stimulates the differentiation of CD4+ ThO cells into either Th1 cells or Th2 cells such as interleukin-4 or an antibody that is capable of binding interferon gamma; treating HIV infections |
| 07/21/2005 | US20050158340 Recombinant RSV virus expression systems and vaccines |
| 07/21/2005 | US20050158339 Vaccines against Escherichia coli O157 infection |
| 07/21/2005 | US20050158338 Both human and bovine polynucleotide sequences, as well as a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large polymerase protein (L), and a RNA polymerase elongation factor combined with heterologous gene(s); vaccines |
| 07/21/2005 | US20050158336 Antigenic peptides, e.g. fusion peptides of CTL epitope peptides and a T helper peptide, conjugated to an immunostimulatory DNA oligomer; cytosine-phosphate-guanosine (CpG); enhanced recognition of the substance by the immune system e.g. HIV vaccines, cancer vaccines |
| 07/21/2005 | US20050158335 Polynucleotides from a gene cluster encoding pilin polypeptides; treating or immunizing against infections such as otitis media; antibodies, assays |
| 07/21/2005 | US20050158334 Vaccines comprising aluminium adjuvants and histidine |
| 07/21/2005 | US20050158332 MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
| 07/21/2005 | US20050158331 Autogenous vaccine derived from one's own hypothalamus of the brain & kidney's via a process known as liquefaction |
| 07/21/2005 | US20050158330 water in oil in water (w/o/w) emulsion; polyethylene glycol outer aqueous phase; low viscosity for easier injection; storage stability; less topical response at the injection site; high immunological effect |
| 07/21/2005 | US20050158329 Novel phytol derived immunoadjuvants and their use in vaccine formulations |
| 07/21/2005 | US20050158328 Antigen presenting cells; immunogens; frozen container |
| 07/21/2005 | US20050158327 Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection |
| 07/21/2005 | US20050158325 Comprises imidazonaphthyridine amine, oxazoloquinoline amine, thiazoloquinoline amine, oxazolopyridine amine, thiazolopyridine amine, oxazolonaphthyridine amine, or thiazolonaphthyridine amine derivatives |
| 07/21/2005 | US20050158323 Via antibodies specific for antigen C35; host cells |
| 07/21/2005 | US20050158322 Single chain Fv antibody fragments; for diagnosis/prognosis of human colorectal tumors |
| 07/21/2005 | US20050158321 Drug screening; for methotrexate resistant patients |
| 07/21/2005 | US20050158317 Novel proteins with il-6 inhibiting activity |
| 07/21/2005 | US20050158316 For treating hemorrhagic shock |
| 07/21/2005 | US20050158315 Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore |
| 07/21/2005 | US20050158314 For treating chronic immune system disorders, inhibiting rejection of transplanted tissue |
| 07/21/2005 | US20050158313 Immunoglobulins; competitive binding; gene expression inhibition; for prevention and treatment of gastrointestinal tract cancers, inflammatory bowel disorders, and diabetes |
| 07/21/2005 | US20050158311 Via contacting cell with agent that binds Ryk polypeptides, inhibiting signal transduction; for amelioration of cancer |
| 07/21/2005 | US20050158309 Gonadotropin-releasing hormone (gnrh); gene expression inhibition; for treatment of T-cell related neoplastic diseases |
| 07/21/2005 | US20050158308 For treating, preventing, or ameliorating bone-related or cartilage-related diseases such as osteoporosis; transgenic, knock-out mammals; immunization |
| 07/21/2005 | US20050158305 Monoclonal antibody for treatment of cancer, autoimmune diseases and rheumatoid arthritis; complementarity determining regions |
| 07/21/2005 | US20050158304 chimeric or humanized antibody that specifically binds to an epitope witin residues 1-3 of A beta and a carrier, especially for sustained release |
| 07/21/2005 | US20050158303 Antibody; stability, reduced viscosity, turbidity, istonic, stability; administering under skins |
| 07/21/2005 | US20050158277 Method to genetate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production |
| 07/21/2005 | US20050158276 Bordetella pertussis antigen consisting lipopolysaccharide, pertusis toxin, filamentous hemagglutinin, pertactin or abosrbed to alum; interleukin-12 ; enhances cell-mediated immunity in a host |
| 07/21/2005 | US20050158244 Cell population from staining a neoplastic cell population with a first marker, staining a dendritic cell population with a second marker, fusing the cells to obtain hybrid cell population stained with both markers; purifying |
| 07/21/2005 | US20050158242 Detecting presence of selected cancer by measuring levels of Cancer Specific Genes(CSG) in cells, tissues or bodily fluids and comparing levels with levels of CSG from normal human control, wherein change in measured levels is associated with presence of selected cancer; gynecologic and lung cancers |
| 07/21/2005 | US20050158241 Novel method of diagnosing, monitoring, staging, imaging and treating various cancers |
| 07/21/2005 | DE10359352A1 DNA-Sequenz und rekombinante Herstellung des Graspollen-Allergens Lol p 4 DNA sequence and recombinant production of the grass pollen allergen Lol p 4 |
| 07/21/2005 | DE10359351A1 DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden DNA sequence and recombinant production of group 4 major allergens from cereals |
| 07/21/2005 | DE10212867B4 Verwendung Harnstoff-adjuvierter Polypeptide zur Diagnose, Prophylaxe und Therapie Using urea-adjuvanted polypeptides for the diagnosis, prevention and treatment |
| 07/21/2005 | DE10024383B4 Mit toxischen Substanzen beladene dendritische Zellen With toxic substances loaded dendritic cells |
| 07/21/2005 | CA2552188A1 Polypeptides and immunogenic conjugates capable of inducing antibodies against pathogens, and uses thereof |
| 07/21/2005 | CA2551913A1 Autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment |
| 07/21/2005 | CA2551896A1 Formulations of hydrophobic proteins in an immunogenic composition having improved tolerability |
| 07/21/2005 | CA2551877A1 Neutralizing epitope-based growth enhancing vaccine |
| 07/21/2005 | CA2551812A1 Electronic trading data integration and protection system |
| 07/21/2005 | CA2548990A1 Toll-like receptor 4 (tlr4)-neutralizing antibodies |
| 07/21/2005 | CA2548179A1 Methods and compositions for the production of monoclonal antibodies |
| 07/20/2005 | EP1555319A2 Modified nucleic acid sequences and method to increasing mRNA levels and protein expression in cell systems |
| 07/20/2005 | EP1555316A2 Antigen library immunization |
| 07/20/2005 | EP1555271A1 Peptides useful for diagnosis and therapy of TRP-2+ and/or TRP-1+ tumors |
| 07/20/2005 | EP1555270A1 HCV NS3 proteins and nucleic acids |
| 07/20/2005 | EP1554383A1 Recombinant mva strains as potential vaccines against p. falciparum malaria |
| 07/20/2005 | EP1554311A2 Humanized antibodies that recognize beta amyloid peptide |
| 07/20/2005 | EP1554305A1 Prion protein-binding peptide sequences |
| 07/20/2005 | EP1554301A2 Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 |
| 07/20/2005 | EP1553979A1 Ihnv g protein for immune stimulation |
| 07/20/2005 | EP1553978A2 Interacting site for gp41 on gp120 of hiv-1 |
| 07/20/2005 | EP1553976A2 Hiv envelope-cd4 complexes and hybrids |
| 07/20/2005 | EP1553975A2 Optimized fc variants and methods for their generation |
| 07/20/2005 | EP1553966A2 Human papillomavirus polypeptides and immunogenic compositions |
| 07/20/2005 | EP1553912A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/20/2005 | EP1553832A2 Cell separation compositions and methods |
| 07/20/2005 | EP1280521B1 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates |
| 07/20/2005 | EP1259629B1 Recombinant influenza a viruses |
| 07/20/2005 | EP0977586B1 Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| 07/20/2005 | EP0929677B1 Recombinant method for preparing a complete malaria antigen gp190/msp1 |
| 07/20/2005 | EP0910571B1 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 07/20/2005 | EP0869814B1 Stabilisers for live vaccines |
| 07/20/2005 | EP0812191B1 Peptides for the treatment of cancer |
| 07/20/2005 | EP0703785B1 Methods for treating muscle diseases and disorders |
| 07/20/2005 | EP0677295B1 Liposome having oligosaccharide on the surface |
| 07/20/2005 | CN1643380A Use of the MAL protein as a tumour marker |
| 07/20/2005 | CN1643143A Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/20/2005 | CN1643138A Novel cytokine ZCYTOR17 ligand |
| 07/20/2005 | CN1642984A Specific Ab1'-antibodies against tumour-associated antigen CA 125 |
| 07/20/2005 | CN1642983A Antibodies against of C5aR and use thereof |
| 07/20/2005 | CN1642980A Antagonistic anti-hFAS ligand human antibodies and fragments thereof |
| 07/20/2005 | CN1642968A A human ribonucleotide reductase M2 subunit |
| 07/20/2005 | CN1642967A Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| 07/20/2005 | CN1642579A Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
| 07/20/2005 | CN1642571A Virus-like particles of human papillomavirus |
| 07/20/2005 | CN1642567A HIV inhibiting proteins |
| 07/20/2005 | CN1642560A Hyaluronic acid mediated adenoviral transduction |
| 07/20/2005 | CN1641034A Method for preparing tetanus toxin recombinant antigen and its use |
| 07/20/2005 | CN1640497A Swing breeding and respiratory syndrome suicide DNA vaccine and use |
| 07/20/2005 | CN1640494A Method for preparing avian polyvalent nucleic acid vaccine containing multiple virus antigen epitope |
| 07/20/2005 | CN1640493A Leptospira vaccine |
| 07/20/2005 | CN1640492A 一种钩端螺旋体外膜蛋白疫苗 One kind of Leptospira outer membrane protein vaccine |
| 07/20/2005 | CN1211488C Modified plant viruses as vectors of heterologous peptides |
| 07/20/2005 | CN1211487C Mutants of streptococcal toxin A and methods of use |
| 07/20/2005 | CN1211123C Humanized antibodies against leukocyte adhesion molecule VLA-4 |